Citron Publishes the Smoking Gun on Ligand Pharmaceuticals
Price Target of $35
- Last week, Grant’s Interest Rate Observer published a thoughtful piece of journalism that suggested a $20 price target on Ligand Pharmaceuticals. For copyright purposes we cannot republish, but even Ligand management cannot question the credibility and neutrality of Grant’s.
- The article came out as Citron has spent months working on Ligand to get a better understanding of their “shots on goal” business model to determine whether the company’s pipeline is legitimate or nothing but a pipe dream.
- Citron will expose some of the dirtier secrets of Ligand and will explain why Ligand is a company designed for the “lazy investor” whose stock price has 80% downside from its current levels once people READ.
Background
- Ligand began as a biopharmaceutical company that initially tried, but failed, to successfully develop its own drugs. After over a decade as a public company (and an SEC investigation, a delisting from Nasdaq, and several management changes), Ligand changed its strategy to one of acquiring candidate drugs/technologies and forming partnerships to develop them further.
- The value proposition for Ligand is that it is a “smarter” drug company – run by former investment bankers – that farms out the risk and costs of later stage drug development and R&D and commercialization to strategic partners with the expectation of receiving licensing fees when the drugs successfully reach the market.
- We have heard “The Better Mousetrap Pharma” before and you know how that ends.
READ THE FULL REPORT HERE
Citron 2017 / 2018 Reports
Citron Research Backing Up the Sleigh on Facebook
Twitter has become the Harvey Weinstein of Social Media
Everything Has Changed: The Big 5 Canadian Cannabis Companies Have Achieved “Platform Status”
At What Point Is MNK Selective Disclosure Complete Fraud?
NIO short is a Tesla Déjà vu – Path to $12 Should Have Little Resistance
Wayfair Has Become a Case study in Diseconomies of Scale
Citron reverses opinion on Tesla
Long Pyxus International (NYSE:PYX) – Short-Term Price Target of $65
Namaste: Citron has exposed complete FRAUD that underpins the ‘Business’ of Namaste.
Namaste A Party Not to Sell Your Shares
Our Final Word on $TLRY before $50
Cronos The Dark Side of The Cannabis Space
Wayfair: Citron is listening to the smartest guys in the room
Nvidia- The Dog that Finally Caught the Car
Tilray – Next in line in a Budding Cannabis Industry
$TWTR Just Made the Turn and Is Hitting Stride
Citron Research Explains Why AbbVie is on its way to $60.
Citron Exposes History of FRAUD Behind PolarityTE
Citron expects Netflix to dip back to $340
Fitbit: From Fad to Future
Citron Research Initiates Coverage on Snap Inc. Target Price $17
Citron Changes our Position on ROKU
Inogen Needs to Take a Breath
Citron Research is Bullish on the Most Shorted Stock in the World.
Hailiang Education- China Hustle Déjà vu
Wayfair is Growing Enemies Faster than Customers
Wait til the Senate Hears Twitter’s Hidden Secret
Shopify has a BIG Facebook Problem!
Exact Sciences Corp: We admit to being early. But the science won’t be held back.
Citron Responds to Shopify Conference Call.
Citron chimes in on MiMedx. Countdown to formal investigation. $3 price target
Citron Exposes the Dark Side of shopify The FTC will Take Notice
Update – Questions for Ubiquiti CEO on Investor Day
Citron exposes Ubiquiti Networks
Citron Updates GBTC – What Investors NEED to Know
Motorola Solutions – Total Eclipse of the Truth
FDA FAERS Database Posts Huge Rise in Acthar Deaths and Adverse Events
Today reinforces why $W Wayfair shareholders should be concerned. Multi-channel – Valuation – Supply Chain
NVIDIA to Trade Back to $130
Citron Provides New Proof Why Mallinckrodt is on its way to ZERO
Could Blackberry be the Next NVIDIA?
IF YOU DON’T BELIEVE CITRON BELIEVE THE SCIENCE
Citron Research exposes Exact Sciences and PROVES beyond ANY doubt why this stock will soon be cut in half
Citron Exposes the Dirty Illegal Secrets of FleetCor, and Proof the Company is Already in Cover-Up Mode
FleetCor — Or is it FeeCor or FleeceCor?
Citron Exposes More Undisclosed Relationships at TransDigm
Citron Exposes the Vulnerability of Motorola Solutions — Price Target $45
Express Scripts: Rebate System is a Financial Engineering Kickback Scheme
Could TransDigm be the Valeant of the Aerospace Industry?
Lannett: Citron Exposes the Lawsuits that will Wipe Out the Equity
Citron 2016 & 2015 Report Archives
2016 Reports
2015 Reports
